Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective studyDavid Qualls, Gilles Salles, Grzegorz S. Nowakowski et al.|Blood|2023Cited by 47
Tafasitamab and Lenalidomide in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL): Real World Outcomes in a Multicenter Retrospective StudyDavid Qualls, Connie Lee Batlevi, Michael J. Buege et al.|Blood|2022Cited by 20
289 | MULTICENTER REAL‐WORLD OUTCOMES OF FRONTLINE POLA‐R‐CHP IN TREATMENT NAÏVE DLBCLAlex F. Herrera, Liangyi Chen, Sophie Buller et al.|Hematological Oncology|2025Cited by 2
Real-world outcomes of frontline polatuzumab-rchp and impact of frailty in older adults with diffuse large B-cell lymphomaVarun Iyengar, Pallawi Torka, Jomel Meeko Manzano et al.|Blood|2025Cited by 1
Outcomes of Sequential CD19-Directed Therapies in Relapsed and Refractory Large B Cell LymphomaDavid Qualls, Gilles Salles, Nicholas Lambert et al.|Blood|2023Cited by 1